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Introduction: To advise laryngeal carcinoma patients on the most appropriate form of treatment, a tool to
predict survival and local control is needed.
Materials and methods: We performed a population-based cohort study on 994 laryngeal carcinoma
patients, treated with RT from 1977 until 2008. Two nomograms were developed and validated. Perfor-
mance of the models is expressed as the Area Under the Curve (AUC).
Results: Unfavorable prognostic factors for overall survival were low hemoglobin level, male sex, high
T-status, nodal involvement, older age, lower EQD2T (total radiation dose corrected for fraction dose
and overall treatment time), and non-glottic tumor. All factors except tumor location were prognostic
for local control. The AUCs were 0.73 for overall survival and 0.67 for local control. External validation
of the survival model yielded AUCs of 0.68, 0.74, 0.76 and 0.71 for the Leuven (n = 109), the VU Amster-
dam (n = 178), the Manchester (n = 403) and the NKI cohort (n = 205), respectively, while the validation
procedure for the local control model resulted in AUCs of 0.70, 0.71, 0.72 and 0.62. The resulting nomo-
grams were made available on the website www.predictcancer.org.
Conclusions: For patients with a laryngeal carcinoma treated with RT alone, we have developed visual,
easy-to-use nomograms for the prediction of overall survival and primary local control. These models
have been successfully validated in four external centers.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.
Radiotherapy and Oncology 100 (2011) 108–115In laryngeal carcinoma patients, treatment decisions are usually
made by a multidisciplinary team based on guidelines. Patient- and
tumor-related factors that are taken into consideration in this deci-
sion-making process are the TNM-stage, the functionality of the
larynx, and the general condition of the patient (WHO performance
status or Karnofski score) [1]. Though new developments are
appearing in therapy, the primary treatment for early stage laryn-
geal carcinomas is radiotherapy (RT), laser surgery, or limited
surgery. RT, open surgery (with or without postoperative radio-
therapy), or a combination with systemic therapy are the currentdiotherapy, MAASTRO Clinic,
ROW), Maastricht University
he Netherlands.
iosvelazques@maastrichtuni-
nder the Elsevier OA license.treatment options for more advanced cancers. Guidelines are used
in the treatment decision process, and assessment of prognosis and
preserved function are also taken into consideration. Doctors often
predict the prognosis fairly poorly [2–4], and so it is questionable
whether this has an additional value.
Besides the widely used predictors TNM-stage and general con-
dition, other clinical factors are investigated for their prognostic
and predictive value. An example of this is the pretreatment hemo-
globin level. It is well established that patients with lower pre-
treatment hemoglobin levels have worse overall survival and
local control than patients with normal hemoglobin levels [5–8].
Other prognostic factors that are investigated are sex and age [9–
12], with indications that women and younger patients have a bet-
ter prognosis than men and elderly people.
Thus, to assist the doctor in deciding on the most appropriate
treatment form, a tool to predict survival and local control is
needed [13]. We, therefore, aimed to investigate which clinical
A.G.T.M. Egelmeer et al. / Radiotherapy and Oncology 100 (2011) 108–115 109and imaging factors are prognostic for the laryngeal carcinoma
patients we have treated since 1977 with radiotherapy alone. We
hypothesized that it is possible to develop nomograms for the pre-
diction of survival and local control of laryngeal carcinoma patients
treated with radiotherapy alone performing better than a nomo-
gram based on TNM classiﬁcation alone. We tried to validate these
models with four external datasets from the University Hospital of
Leuven (Belgium), the VU University Medical Center of Amsterdam
(The Netherlands), the Christie Hospital, Manchester (UK) and the
Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital,
Amsterdam (The Netherlands). These models will allow for
improvement of the information given to patients about their
prognosis. In the long term the models will allow for tailoring of
the treatment to individual patients (e.g., for the choice surgery-
radiotherapy), when combined with models predicting outcome
after other therapies.
Materials and methods
Patient population
The patient and treatment characteristics of 1051 consecutively
treated patients with a squamous cell laryngeal carcinoma were
recorded in a database from January 1977 to December 2008. All
patients were treated with radiotherapy alone at the MAASTRO
Clinic. Patients with a carcinoma in situ or distant metastasis at
presentation (seven patients) were excluded from the study. Other
exclusion criteria were treatment with Cobalt radiation (nine pa-
tients) and the use of chemotherapy (41 patients, three of whom
had concurrent chemoradiation; 24 neoadjuvant chemotherapy;
and 14 of whom were treated according to the ARCON-trial with
carbogen and nicotinamide). A total of 994 patients were included
in our cohort study. 528 (53.1%) of these patients had a T1 tumor,
264 (26.6%) a T2, 131 (13.2%) a T3, and 71 patients (7.1%) had a T4
tumor. Most of the patients (894, 89.9%) did not have positive
lymph nodes. 45 patients (4.5%) had a N1 status, 42 (4.2%) a N2,
and eleven (1.1%) patients had a N3 status. The trial is registered
on ClinicalTrials.gov with registration number 2263.
Diagnosis and staging were always undertaken according to the
Dutch guidelines, including endoscopia under anesthesia and
biopsy of the tumor. Also recommended in the latest Dutch guide-
lines are a computed tomography (CT) scan of the head and neck, a
chest X-ray, ultrasonography of the neck (if necessary with punc-
tion), and blood tests.Radiotherapy treatment
All patients were treated at the MAASTRO Clinic with a contin-
uous course of radiotherapy delivered by a 4–6 MV linear acceler-
ator after either a traditional simulation (patients before 1996) or a
CT simulation (patients treated from 1996 onwards). During simu-
lation and treatment, all patients were immobilized by a thermo-
plastic mask. Sixteen patients received a palliative radiation dose
of less than 60 Gy. Patients were treated in line with the state-of-
the-art practices. T1–2 glottic tumors and T1 supraglottic tumors
were treated with 60–66 Gy in fractions of 2–2.40 Gy, and other tu-
mors were treated with 70 Gy over seven weeks in daily fractions
of 2 Gy, and after 2000 with 68 Gy, the ﬁrst 23 fractions 2 Gy daily,
and the last 11 fractions twice daily in fractions of 2 Gy.
To correct for differences in radiation scheme, the biological
equivalent dose in fractions of 2 Gy and corrected for overall treat-
ment time was calculated, using the following formula:
EQD2T ¼ D ððdþ a=bÞ=ð2þ a=bÞÞ  cðT  TkÞ
D is the total radiation dose, d is the fraction dose, a/b is 10 Gy, T is
the overall treatment time, accelerated repopulation kick-off time(Tk) is 28 days, and loss in dose due to repopulation (c) is 0.6 Gy/d
[14]. As EQD2T is not easily calculated in daily clinical practice,
EQD2T values for the most common radiation schemes are given
in Table 1. If the overall treatment time for a patient differs from
the anticipated value, it is possible to recalculate EQD2T after com-
pleting the treatment and thus to obtain an adjusted prediction.
The follow-up for all patients consisted of regular visits to the
head and neck oncology department over ﬁve years after the cura-
tive radiotherapy treatment. These visits took place every second
month for the ﬁrst six months, then every third month for two
years, every fourth month during the third year, then twice yearly
until the end of follow-up (ﬁve years). At every visit, the medical
history was taken and physical examination carried out. Thereaf-
ter, information was gathered from the general practitioner and
the Dutch Registry of Births, Deaths, and Marriages (‘‘Gem-
eentelijke Basis Administratie’’, or ‘‘GBA’’).PET–CT analysis
Features of the PET–CT scans were analyzed for a subgroup of
patients. 18FFDG-PET-scans were available since 2004, and 115 of
these scans were available and assessable. Contoured tumor vol-
umes were available for 124 patients, mostly patients with a T3
or T4 tumor. The gross tumor volume (GTV) was measured as con-
toured in our radiotherapy treatment planning system by a radia-
tion oncologist (Computerized Medical Systems, INC, St. Louis,
MO). Several features were extracted from the pretreatment PET-
scans. A circle was drawn around the region of interest c.q. the lar-
ynx. Within this region of interest the maximal Standard Uptake
Value (SUVmax) is given. Dedicated software (TrueD; Siemens Med-
ical, Erlangen, Germany) was used to calculate SUVmax per patient.
Furthermore, the SUV of the deltoid muscle was calculated. The
SUVmax of the tumor and the SUV of the background was used to
calculate a source-to-background ratio according to the following
formula:
78:13  ðSUVtumor=SUVbackgroundÞð0:2988Þ
The output of the formula is expressed as a percentage, which was
used as the contouring percentage to determine the metabolic vol-
ume, i.e., the volume of the tumor that has higher FDG uptake than
the contouring percentage of the SUVmax.Statistical analysis
The prognostic factors tested were age at start of radiotherapy,
sex, tumor location (glottic or non-glottic), pretreatment hemoglo-
bin level, EQD2T, T-stage, and N-stage (N0 or N+). Age, hemoglobin
level, and EQD2T were analyzed as continuous values. The end-
points of the study were overall survival and local control, both cal-
culated from the start of radiotherapy. Patients were followed for
at least 1 month up to a maximum of 72 months. Failure of local
control was deﬁned as persistent or recurrent local disease after
the start of radiotherapy (i.e., the ﬁrst relapse after therapy).
The Kaplan–Meier method was used for univariate survival
analysis. For overall survival, data were considered right-censored
if patients were still alive at the time of evaluation. For local con-
trol, data were considered right-censored if patients did not have
recurrent local disease at the time of evaluation. Groups were com-
pared using the log rank test. The Cox proportional hazards model
was applied to perform a multivariate analysis. The proportional
hazards assumption was tested by adding time-dependent covari-
ates to the model. In addition, linearity of the variables was as-
sessed. Missing values were imputed using predictive mean
matching. A stepwise backward method was used to select a rele-
vant set of variables (p < 0.2). Hazard ratios and 95% conﬁdence
intervals were reported. Performance of the models was expressed
Table 1
EQD2T of the most common radiotherapy schemes.
Radiotherapy scheme EQD2T
60 Gy in fractions of 2 Gy in 6 weeks 60  ((2 + 10)/(2 + 10))  0.6 (40  28) = 52.8 Gy
66 Gy in fraction of 2 Gy in 6.5 weeks 66  ((2 + 10)/(2 + 10))  0.6 (45  28) = 55.8 Gy
68 Gy, 23 fractions of 2 Gy once daily, and 11 fractions of 2 Gy twice daily, in 6 weeks 68  ((2 + 10)/(2 + 10))  0.6 (39  28) = 61.4 Gy
70 Gy in fractions of 2 Gy in 7 weeks 70  ((2 + 10)/(2 + 10))  0.6 (47  28) = 58.6 Gy
55 Gy in fractions of 2.2 Gy in 5 weeks 55  ((2.2 + 10)/(2 + 10))  0.6 (33  28) = 53.9 Gy
110 Nomogram for laryngeal carcinoma patientsas the C-statistic (Harrell’s C), which is comparable to the Area
Under the Curve (AUC). The maximum value of the C-statistic is
1.0; indicating a perfect prediction model. A value of 0.5 indicates
that 50% of the patients are correctly classiﬁed (i.e., as good as
chance). Bootstrapping techniques were used to validate the mod-
els; that is, to adjust the estimated model performance for over-
optimism or overﬁtting. The results of the multivariate analysis
were used to develop a nomogram. These nomograms will be, after
publication, publicly available on the website www.predictcan-
cer.org. The MAASTRO cohort was split into four subgroups accord-
ing to quartiles of the risk score. To assess for differences in
survival of the subgroups, Kaplan–Meier curves were made. In
addition, the performance of the multivariate model was assessed
using four external validation sets [15]. Analyses were performedTable 2
Patient characteristics.
MAASTRO cohort Leuven cohort VU A
Number (%) Number (%) Numb
Age
18–60 years 360 (36.2) 40 (36.7) 62 (
>60 years 634 (63.8) 69 (63.3) 116(
Gender
Male 883 (88.8) 99 (90.8) 154 (
Female 111 (11.2) 10 (9.2) 24 (
T-classiﬁcation
T1 528 (53.1) 45 (41.3) 67 (
T2 264 (26.6) 30 (27.5) 91 (
T3 131 (13.2) 24 (22.0) 16
T4 71 (7.1) 10 (9.2) 4
N-classiﬁcation
N0 894 (89.9) 82 (75.2) 165 (
N1 45 (4.5) 6 (5.5) 5
N2 42 (4.2) 18 (16.5) 6
N3 11 (1.1) 3 (2.8) 0 (
Missing 2 (0.2) 0 (0) 2
Location tumor
Glottic 729 (73.3) 64 (58.7) 127 (
Supraglottic 245 (24.6) 39 (35.8) 43 (
Subglottic 13 (1.3) 2
Transglottic 7 (0.7) 6
Other 6 (5.5)
Hemoglobin level
Lowa 168 (16.9) 20 (18.3) 44 (
Normal-high 667 (67.1) 46 (42.2) 123 (
Missing 159 (16.0) 43 (39.4) 11
Total radiation dose
<60 Gy 16 (1.6) 45 (41.3) 1
60–66 Gy 437 (44.0) 12 (11.0) 69 (
>66 Gy 541 (54.4) 52 (47.7) 108 (
Fraction dose
1.6–2.0 677 (68.1) 65 (59.6) 116 (
>2.0 317 (31.9) 44 (40.4) 62 (
Overall treatment time
<40 days 321 (32.3) 43 (39.4) 164 (
40–50 days 595 (59.9) 41 (37.6) 11
>50 days 78 (7.8) 25 (22.9) 3
a Male < 8.5 mmol/L, female < 7.5 mmol/L.using SPPS for Windows (version 17.0; SPSS Inc., Chicago) and Mat-
lab 7.11.0 (The MathWorks Inc., Natick, MA, USA).Validation datasets
Patient characteristics of the validation cohorts are shown in
Table 2. The validation cohort of Leuven consisted of 109 laryngeal
carcinoma patients, treated with radiotherapy alone between
March 2000 and January 2006. 45 of these patients (40.9%) had a
T1 tumor, and 83 patients (75.5%) did not have nodal involvement.
None of the patients received chemotherapy. Two thirds of the pa-
tients received 2 Gy fraction until a total dose of 66–72 Gy. Most
other patients were treated with 25 fraction of 2.2 Gy, to reach a
total dose of 55 Gy.msterdam cohort NKI/AVL Amsterdam cohort Manchester cohort
er (%) Number (%) Number (%)
34.8) 75 (36.5) 154 (38.2)
65.2) 130 (63.5) 249 (61.8)
86.5) 162 (79.1) 357 (88.6)
13.5) 43 (20.9) 46 (11.4)
37.6) 86 (41.9) 252 (62.5)
51.1) 119 (58.1) 124 (30.8)
(9.0) 0 (0.0) 27(6.7)
(2.2) 0 (0.0) 0 (0.0)
92.7) 184 (89.8) 398 (98.8)
(2.8) 6 (2.9) 1 (0.2)
(3.4) 11 (5.4) 3 (0.7)
0) 4 (1.9) 1 (0.2)
(1.1) 0 (0.0) 0 (0.0)
71.3) 149 (72.7) 403 (100.0)
24.2) 56 (27.3) 0 (0.0)
(1.1)
(3.4)
0 (0.0)
24.7) 35 (17.1) 90 (22.3)
69.1) 145 (70.8) 255 (63.3)
(6.2) 25 (12.1) 58 (14.4)
(0.6) 2 (0.9) 402 (99.8)
38.8) 94 (45.9) 1 (0.2)
60.7) 109 (53.2) 0 (0.0)
65.2) 0 (0.0) 1 (0.2)
34.8) 205 (100) 402 (99.8)
92.1) 162 (79.1) 401 (99.5)
(6.2) 38 (18.5) 2 (0.5)
(1.7) 5 (2.4) 0 (0.0)
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treated between December 2001 and January 2007. 67 (37.6%) had
a T1 tumor and 165 patients (92.7%) were N0. 97 patients were
treated with two lateral ﬁelds and 19 patients with an IMRT tech-
nique. All patients were treated with radiotherapy alone, with
most patients treated with 2 Gy fraction, until 68–70 Gy or 60 Gy
in 2.5 Gy fractions.
The NKI/AVL Amsterdam cohort consisted of 205 patients with
early larynx cancer (T1 tumors in 42% of cases, T2 tumors in 58% of
cases) treated with primary radiation treatment between March of
2000 and July 2008. 184 patients (89.8%) were N0 at presentation.
Patients with T1N0 glottic cancer were treated with 2 lateral
opposing beams to the larynx only. The standard fractionation
scheme for these patients was 25 fractions of 2.4 Gy to a total dose
of 60 Gy in 5 weeks. Patients with T2 glottic cancers or with supra-
glottic cancer received radiation treatment to the larynx including
prophylactic neck irradiation. The fractionation schedule for this
latter group was 35 fractions of 2 Gy to a total dose of 70 Gy in
6 weeks, according to the DAHANCA schedule [16]. None of the pa-
tients received chemotherapy.
The Manchester cohort consists of 403 patients, which were
treated between January 1998 and January 2005. All these patients
had a glottic tumor and most of these tumors were small (252
(62.05%) T1 tumors and 124 (30.8%) T2 tumors). All but four pa-
tients (1.2%) were N0. 189 patients received radiation through
two lateral opposing ﬁelds and 240 patients were treated with
an anterior oblique technique. The majority of patients with
treated with 50–55 Gy, in 16 fractions (3.1–3.4 Gy per fraction).Results
MAASTRO cohort
Analyses were carried out for 994 patients of the MAASTRO co-
hort. The majority of the patients were male (88.8%) and the med-
ian age at the start of radiotherapy was 65.0 years (range 31–
91 years). Pretreatment hemoglobin level was available for 835 pa-
tients; this value was missing in 16.0% of cases. For more patient
information, see Table 2.
At the time of analysis, 476 patients were alive (47.9%). Median
follow-up for surviving patients was 72 months (range 2–
72 months). Two-year overall survival was 82.8%, and ﬁve-year
overall survival was 67.7%. Primary local control was 71.0% at
two years and 54.0% at ﬁve years after the start of treatment. A to-
tal of 220 local failures were observed. Most of these (179/220,Table 3
Multivariate analysis of potential prognostic factors.
Overall survival
Hazard ratio Conﬁdence intervals p-
Age 1.04 1.03–1.05 <0
Gender 0
Female 1.00
Male 2.30 1.49–3.55
T-stage <0
T1 1.00
T2 1.22 0.91–1.63
T3 2.22 1.56–3.14
T4 4.29 2.85–6.47
N-stage 0
N0 1.00
N-positive 1.46 1.03–2.06
Location tumor 0
Glottic 1.00
Non-glottic 1.31 0.98–1.75
Hemoglobin level 0.67 <0
EQD2T 0.97 0.94–0.99 081.4%) occurred within the ﬁrst two years after treatment, and
no local failures were recorded after ﬁve years as they are assumed
to be second primary tumors.Prognostic factors
Univariate Cox regression was carried out on the following fac-
tors: age at the start of radiotherapy, sex, tumor location, pretreat-
ment hemoglobin level, EQD2T, T-stage, and N-stage (N0 or N+). All
factors were statistically signiﬁcant for overall survival (p < 0.05).
In the multivariate analysis, independent unfavorable prognostic
factors for overall survival were low hemoglobin level, male sex,
high T-status, presence of nodal involvement, older age, lower
EQD2T, and non-glottic tumor. See Table 3 for the hazard ratios,
conﬁdence intervals and p-values.
The year of therapy had no prognostic signiﬁcance for either
survival (p = 0.28) or local control (p = 0.48). In order to test the
hypothesis that modern radiotherapy (3D, in vivo dosimetry)
would perform better than 2D radiotherapy, the cohort was split
before (n = 532) and after January 1996 (n = 462). In the univariate
analysis there was no difference between the two groups
(p = 0.14), but in the Cox regression analysis there was a trend
(p = 0.077) with a hazard ratio of 1.3 in favor of modern
radiotherapy.
The clinical factors investigated for local control were the same
as for overall survival. Tumor location (i.e., glottic vs non-glottic)
was signiﬁcant in the univariate analysis (p < 0.001), but not in
the multivariate analysis (p = 0.93). All other factors were signiﬁ-
cant both in the univariate and in the multivariate analysis. Unfa-
vorable prognostic factors for local control were low hemoglobin
level, male sex, high T-status, nodal involvement, older age, and
lower EQD2T. See Table 3 for the hazard ratios, conﬁdence intervals
and p-values.PET–CT scans
Tumor volume was measured in only 124 patients. The GTV
ranged between 0.0 and 128.2 cc with a median of 4.7 cc. In a sub-
group analysis with these patients, the volume was a statistically
signiﬁcant predictor for overall survival (p < 0.001) and local con-
trol (p < 0.001). In the Cox regression analysis, we tested the prog-
nostic value of tumor volume, sex, and N-status. None of these
factors was statistically signiﬁcant for either overall survival, or
for local control. This subgroup is possibly too small to detect inﬂu-
ences on overall survival or local control.Local control
Value Hazard ratio Conﬁdence intervals p-Value
.0001 1.02 1.01–1.03 0.0012
.0002 <0.0001
1.00
2.47 1.69–3.60
.0001 <0.0001
1.00
1.52 1.20–1.92
2.48 1.87–3.28
4.28 3.05–6.02
.034 0.0059
1.00
1.51 1.13–2.03
.0725
1.00
– 0.93
.0001 0.75 0.67–0.85 <0.0001
.0037 0.97 0.95–0.99 0.0011
112 Nomogram for laryngeal carcinoma patientsOne-hundred and ﬁfteen PET-scans were assessable and evalu-
able. SUVmax ranged between 1.9 and 23.8, with a median of 6.1.
The metabolic volume ranged between 1.1 and 73.3 cc, with a
median of 7.9 cc. The SUVmax and metabolic volume were not sta-
tistically signiﬁcant for survival (p = 0.093 and p = 0.93, respec-
tively), but SUVmax was a statistically signiﬁcant predictor for
local control (p = 0.019, metabolic volume: p = 0.70). In the Cox
Regression analyses, the SUVmax lost signiﬁcance, when corrected
for T-status, N-status and GTV. GTV, T-status and the SUVmax are
highly correlated.Nomograms
Two nomograms were built, one for prediction of survival
(Fig. 1) and one for local control (Fig. 2). The AUCs of the models
were 0.73 and 0.67, respectively. The AUC corrected for overﬁtting
by the bootstrap procedure was 0.73 for overall survival and 0.67
for local control. For the purpose of comparison, we analyzed the
predictive value of the TNM-stage alone. The AUC of the model
for overall survival was 0.62, which means that the model pre-
dicted overall survival correctly in only 62% of patients. The AUC
of the model for local control was 0.62 too.
The MAASTRO cohort can be split into four subgroups, accord-
ing to the quartiles of the risk score. The prognoses of the high-
and low-risk groups are distinctive, but the other two groups have
overlapping 95% conﬁdence intervals. They are, therefore, merged
into one patient group with a medium risk score. The two- and
ﬁve-year survival rates were 82.1% (95% CI, 76.8–87.4%) and 76.3Fig. 1. Nomogram for the prediction of(95% CI, 70.4–82.2%) for the low-risk group, 72.1% (95% CI, 67.8–
76.4%) and 53.3% (95% CI, 48.6–58.4%) for the medium-risk group,
and 47.3% (95% CI, 40.4–54.2%) and 28.3% (95% CI, 21.8–34.8%) for
the high-risk group, respectively (p < 0.001). See Fig. 3 for the Kap-
lan–Meier curve.
We validated these models with the datasets of Leuven, VU and
NKI Amsterdam and Manchester. Validation of the survival model
yielded AUCs of 0.68, 0.74, 0.71 and 0.76, while the validation pro-
cedure for the local control model resulted in AUCs of 0.70, 0.71,
0.62 and 0.72, respectively. We validated the TNM model on the
other datasets. The AUCs of the survival TNM model were 0.70
for the Leuven database, 0.65 for the VU Amsterdam database,
0.57 for the NKI database and 0.63 for the Manchester database.
The local control TNM model yielded AUCs of 0.62, 0.64, 0.56 and
0.63, respectively. Conﬁdence intervals are shown in Table 4.Discussion
We have developed visual, ready-to-use nomograms for overall
survival and primary local control in laryngeal carcinoma patients
to predict outcome following radiotherapy alone. We did so after a
multivariate analysis of several easily assessable clinical factors in
a large group of unselected laryngeal cancer patients. The survival
rates in this study are comparable with other studies and with
those in the Dutch Cancer Registration (Nederlandse Kankerregis-
tratie) [17], which observed a two- and ﬁve-year overall survival
of 81% and 69%, respectively. The models we developed for both2-year and 5-year overall survival.
Fig. 2. Nomogram for the prediction of 2-year and 5-year local control.
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tient populations in hospitals in Leuven (Belgium), Amsterdam
(The Netherlands), and Manchester (UK). The models perform bet-
ter than models based on TNM staging alone.
Johansen et al. [18] performed a multivariate analysis on 1127
patients with a laryngeal carcinoma treated with curative radio-
therapy alone. This group of patients is comparable to ours with re-
spect to age, sex, TNM-stage and tumor location. As in our patient
population, they found sex, T-stage, N-stage, and hemoglobin level
to be statistically signiﬁcant for overall survival. They also found
differentiation grade to be signiﬁcant for survival, but this value
was not available for our patients. And unlike our data, the hemo-
globin level was not prognostic for local control.
In 2001 a study was published about a prediction model for
head and neck cancer patients [19]. This model was based on
1662 head and neck cancer patients, using age, sex, cTNM-status,
tumor (sub)site, and history of tumor as predictors for survival.
However, because the performance of the model is not indicated,
its accuracy is unknown. Other studies with smaller groups of pa-
tients found correlations between outcome and T-site [20], low
pretreatment hemoglobin level [5–7], and tumor volume [20–
22]. Along with clinical factors, imaging features [23–25], serum
markers [26,27] and other biomarkers [28–30] also have a predic-
tive value for laryngeal carcinoma.
Several studies have been published with different ﬁndings
about the predictive value of the PET–CT scan in head and neck
cancer [31,32]. In contrast to earlier studies, our population con-
sists exclusively of patients with a laryngeal carcinoma. Even
though there are similarities between the different tumors in thehead and neck region, there are also a number of differences.
Therefore, it is not possible to perform prognostic and predictive
studies without adequate stratiﬁcation for location of the tumor.
In the group of patients in this study, GTV was a signiﬁcant prog-
nostic factor for survival in the univariate analysis. The prognostic
factors for local control in the univariate analysis were SUVmax and
GTV.
This study is an observational – ‘‘population-based’’ cohort
study, which included all laryngeal carcinoma patients treated
with radiotherapy alone at our hospital. There is a potential selec-
tion bias, because treatment choice was made before inclusion in
the study. During the inclusion period there were changes in diag-
nostics, staging methods, and treatment choice, which imply that
there might be stage migration. Although treatment quality and
control have improved in recent decades, we observed no signiﬁ-
cant improvement of overall survival over the course of this study.
A possible explanation for this is that co-morbidity in laryngeal
carcinoma patients is high and inﬂuences overall survival more
than the cancer itself. Data on WHO performance status or Karnof-
ski score were missing in our population, thus we were not able to
incorporate the effect of co-morbidity on the predictive nomogram
which may limit its predictive performance. Although co-morbid-
ity would certainly inﬂuence the estimation of overall survival,
our estimation based on the predictive nomogram yielded similar
AUCs on the external datasets and was signiﬁcantly superior to
TNM for overall survival prediction. Co-morbidity might be an
important predictor and should be investigated in future studies.
Patients treated with chemotherapy were excluded from this
analysis, as they constituted only a small group of patients. Most
Fig. 3. Kaplan Meier curve for overall survival according to the different prognosis
groups.
Table 4
Nomograms performance in external datasets.
Survival Local control
Model based on multiple variables Model based on TNM Model based on multiple variables Model based on TNM
MAASTRO (n = 994)
(95% CI)
0.73
(0.70–0.77)
0.62
(0.58–0.63)
0.67
(0.64–0.71)
0.62
(0.55–0.63)
Leuven (n = 109)
(95% CI)
0.68
(0.50–0.82)
0.70*
(0.45–0.81)
0.70
(0.50–0.78)
0.62
(0.49–0.72)
VU Amsterdam (n = 178)
(95% CI)
0.74
(0.69–0.87)
0.65
(0.57–0.75)
0.71
(0.66–0.81)
0.64
(0.57–0.74)
NKI/AVL Amsterdam (n = 205)
(95% CI)
0.71
(0.60–0.82)
0.57
(0.52–0.69)
0.62
(0.55–0.75)
0.56
(0.49–0.63)
Manchester (n = 403)
(95% CI)
0.76
(0.72–0.81)
0.63
(0.58–0.69)
0.72
(0.67–0.78)
0.63
(0.58–0.69)
Pooled external datasets 0.71
(0.70–0.76)
0.60
(0.57–0.62)
0.65
(0.62–0.68)
0.60
(0.58–0.61)
* Conﬁdence intervals were obtained in a bootstrap procedure (n = 1000). The obtained AUCs were signiﬁcantly different for the multivariate model compared with the TNM
based model for every cohort (p 0.001), except for survival prediction in the Leuven cohort where no signiﬁcant differences were found.
114 Nomogram for laryngeal carcinoma patientsof them received chemotherapy as a palliative treatment or within
a study protocol. A recent meta-analysis demonstrates the beneﬁt
of concurrent chemotherapy [33–36], with an absolute beneﬁt of
6.5% at ﬁve years for head and neck cancer patients. In subgroup
analyses this effect seems stronger for younger patients (<60 years
old) and patients with good performance status and locally ad-
vanced disease.
To allow for adequate decision making regarding treatment for
laryngeal cancer patients, we are currently analyzing our data on
patients with a laryngeal carcinoma treated with laser surgery or
surgery, and patients treated with surgery and postoperative
radiotherapy. By making nomograms for these patients too, we
can create a useful tool for the treatment decision-making process.
A model consisting of solely clinical features is still too limited to
allow clinical decision making. There is a need for adding biological
and imaging data [29]. There is a need for a prospective multicen-tric randomized trial, preferably with banking of tissues, to vali-
date and extend the results. A prognostic study of that kind
would make it possible to collect data on biomarkers and imaging
features, along with clinical data. Normal tissue reactions should
then also be taken into account [37–39]. The availability of several
validated nomograms for the different therapeutic options for lar-
yngeal carcinoma consisting of clinical, biological, and imaging fea-
tures will make a potent decision support model. The risk groups
illustrated in Fig. 3 can also be used for stratiﬁcation in clinical tri-
als or to customize more aggressive strategies to the risk of relapse.Conclusions
We have built visual, ready-to-use nomograms for the predic-
tion of survival and primary local control with several easy assess-
able clinical factors, for use on patients with laryngeal carcinoma
treated with radiotherapy alone. The performance of these nomo-
grams is signiﬁcantly better than the predictive value of the TNM-
classiﬁcation alone, but still need additional data before being used
in clinical practice.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.radonc.2011.06.023.
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